Claims for Patent: 8,454,956

Summary for Patent: 8,454,956

Title:	Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
Abstract:	The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors.
Inventor(s):	Chang; Ming-Shi (Tainan, TW)
Assignee:	National Cheng Kung University (Tainan, TW)
Application Number:	12/869,224
Patent Claims:	1. A method for treating osteoporosis in an individual comprising administering to the individual an effective amount of an antibody that specifically binds to IL-20 or an antigen binding fragment thereof. 2. The method of claim 1, wherein the antibody or antigen binding fragment specifically binds to human IL-20 (SEQ ID NO:6). 3. The method of claim 1, wherein the antibody is a humanized antibody. 4. The method of claim 1, wherein the antibody is a chimeric antibody. 5. The method of claim 1, wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab', a F(ab').sub.2 and a Fv. 6. The method of claim 1, wherein the osteoporosis is associated with estrogen deficiency. 7. The method of claim 6, wherein the estrogen deficiency is associated with menopause. 8. The method of claim 1, wherein the osteoporosis is associated with androgen deficiency. 9. The method of claim 1, wherein the antibody that specifically binds to IL-20 or the antigen binding fragment thereof is administered in combination with another therapeutic agent. 10. The method of claim 9, wherein the other therapeutic agent is a TNF.alpha. antagonist. 11. The method of claim 10, wherein the TNF.alpha. antagonist is selected from the group consisting of an etanercept polypeptide, infliximab and adalimumab. 12. The method of claim 9, wherein the another therapeutic agent is an IL-20 R1 antagonist, an IL-20 R2 antagonist, or an IL-22 R1 antagonist. 13. The method of claim 12, wherein the IL-20 R1 antagonist is an anti-IL-20 R1 antibody, the IL-20 R2 antagonist is an anti-IL-20 R2 antibody, and the IL-22R1 antagonist is an anti-IL-22R1 antibody.

Details for Patent 8,454,956

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2029-08-31
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2029-08-31
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2029-08-31
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2029-08-31
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2029-08-31
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2029-08-31